Transmission system operator TenneT has agreed to sell a 25.1% stake in its German subsidiary to the German Government, facilitated by Kreditanstalt für Wiederaufbau (KfW), for approximately €3.3bn ($3.9bn). The transaction, which follows an earlier €9.5bn commitment from institutional investors including APG, GIC and Norges Bank Investment Management, is expected to enhance TenneT Germany's financial standing and support essential infrastructure management within the country. The sale will adhere to th ...

Core Viewpoint - Northern Trust Corporation (NASDAQ:NTRS) is currently considered one of the most undervalued quality stocks, with recent price target increases from multiple analysts despite varying ratings [1][2][3]. Analyst Ratings and Price Targets - Goldman Sachs raised its price target for Northern Trust to $148 from $130 while maintaining a Sell rating [1]. - Citi increased its price target to $162 from $143, keeping a Neutral rating, following a Q4 2025 earnings beat with an EPS of $2.42 and revenue of $2.14 billion [2]. - TD Cowen raised its price target to $175 from $165 with a Buy rating, citing a Q4 2025 core EPS of $2.62 that exceeded expectations due to higher pre-tax pre-provision income and lower provision expenses [3]. Company Overview - Northern Trust Corporation is a financial holding company that provides wealth management, asset servicing, asset management, and banking solutions for various clients, operating in two segments: Asset Servicing and Wealth Management [4].

A Citi economist was berated by Indonesia for lacking a PhD, highlighting growing pressure on analysts who publish critical research https://t.co/xqcBkKi7SU ...

Group 1 - Sanofi SA is considered one of the best cheap stocks to buy for 2026 according to Citi Research, which initiated coverage of six large European pharmaceutical stocks including Sanofi [1] - Citi assigned Sanofi a Neutral rating with a price target of €85, indicating concerns about the company's drug development progress and a weakened long-term growth outlook due to pipeline setbacks [2][3] - The current valuation of Sanofi is approximately 10 times expected 2026 earnings, reflecting the setbacks in its pipeline, and the market is unlikely to reward the stock with a higher multiple without tangible evidence of improvement [3] Group 2 - Sanofi reported positive results for its experimental medicine amlitelimab in Phase 3 clinical studies for moderate-to-severe atopic dermatitis, with data coming from two major global trials, SHORE and COAST 2 [4] - The results from the studies indicate that amlitelimab was generally well tolerated, with side effects consistent with previous findings [4] - Sanofi operates in various segments including specialty care, vaccines, and general medicines, focusing on the research, development, manufacturing, and marketing of pharmaceutical products [5]

Core Viewpoint - Bullish (NYSE:BLSH) is set to release its fourth-quarter earnings for 2025, with analysts anticipating a significant increase in earnings per share and quarterly revenue compared to the previous quarter [1][2]. Market Estimates - Analysts project earnings per share of $0.15 for Bullish, up from $0.10 in the previous quarter [2]. - The expected quarterly revenue is $87.77 million, an increase from $76.60 million in the third quarter [2]. Stock Performance and Analyst Ratings - The consensus price target for BLSH stock is $53.36, based on 12 analysts, with Citigroup providing the highest forecast of $67 [3]. - The average price target from the three most recent ratings is $53.67, indicating approximately 85% upside potential for the stock [3]. Sentiment and Indicators - As of December 31, short interest in BLSH stock was 7.15 million shares, representing 15.6% of the company's publicly available float, reflecting a high level of bearish sentiment [4]. - The Commodity Channel Index indicates oversold conditions, suggesting a potential "Buy" signal [4]. - The Moving Average Convergence Divergence indicator has flashed a "Sell" signal, while the Relative Strength Index remains "Neutral" [5]. Company Overview - Bullish operates a cryptocurrency exchange focused on institutional clients and owns CoinDesk, a notable cryptocurrency media and data brand [5]. - The company is led by former NYSE Group president Thomas Farley [5]. Trading Volume and Price Action - Bullish reported a total trading volume of $222.4 billion, including spot and derivatives, for the quarter ending December 31, marking a 56% increase from the previous quarter [6]. - Shares of Bullish rose 0.80% in after-hours trading after a 4.74% decline during the regular trading session, closing at $28.77 [6]. - The stock has shown a weaker price trend over short, medium, and long terms according to Benzinga's Edge Stock Rankings [6].

Group 1 - Broadcom Inc. (NASDAQ:AVGO) is included in the Ken Fisher Stock Portfolio as one of the 12 best stocks to buy [1] - Fidelity Investments and Broadcom reached a legal agreement regarding essential software access, resolving a dispute that arose after Broadcom's acquisition of VMware in 2023 [2] - Citi maintains a Buy rating on Broadcom with a price target of $480, citing increasing AI sales as a key factor, despite the stock being down 4.86% year-to-date as of January 29, 2026 [3] Group 2 - The company is recognized as one of the leading semiconductor businesses globally and has expanded into infrastructure software [3] - There are opinions suggesting that while Broadcom has potential, certain AI stocks may offer greater upside potential with less downside risk [4]

Market Overview - The S&P 500 index briefly crossed 7000 points for the first time on January 28, 2026, rebounding nearly 40% since April 2025 lows, with five record closes noted by January 27, 2026 [1] - The Nasdaq Composite has seen modest gains in 2026, while the Russell 2000 has surged nearly 7% year-to-date as of January 29, 2026, outperforming large-cap peers for 14 consecutive trading sessions, the longest streak since 1996 [2] Valuation Concerns - The Shiller S&P 500 price-to-earnings ratio is currently at 41, the highest since the dot-com bubble, while the trailing P/E ratio is at 31.52, significantly above the historical average of 16.2 [3] - Bank of America's head of US equity strategy, Savita Subramanian, indicates that the S&P 500 is expensive, predicting it will reach 7,100 by year-end 2026, which is among the lowest forecasts on Wall Street [3] Investment Strategy - Goldman Sachs analysts predict that value stocks will remain favored if US economic momentum strengthens, noting that these stocks, with forward P/E ratios below 15, have outperformed higher-valuation stocks at the start of the year, achieving a 15% return in the last six months of 2025 [4] Stock Selection Methodology - The list of best cheap stocks for 2026 was created using screeners like TradingView and Finviz, focusing on US-listed stocks with forward P/E ratios between 3 and 15 and a positive upside potential of at least 20%, ranked by hedge fund holdings as of Q3 2025 [7][8] HNI Corporation - HNI Corporation (NYSE:HNI) is highlighted as a top cheap stock for 2026, with a forward P/E of 11.92 and an upside potential of 58.46% [9] - Benchmark Co. raised its price target for HNI to $75 per share from $60, citing a planned acquisition of Steelcase Inc. valued at approximately $2.2 billion, expected to yield annual cost synergies of about $120 million [10] - HNI's shares are priced below historical values, with a P/E ratio of 13.35, and the company has a history of consistent dividend payments over 55 years [11] Sanofi SA - Sanofi SA (NASDAQ:SNY) is also listed as a cheap stock for 2026, with a forward P/E of 9.02 and an upside potential of 25.11% [15] - Citi Research initiated coverage on Sanofi with a Neutral rating and an €85 price target, expressing concerns over pipeline setbacks affecting long-term growth [16] - Sanofi's current valuation reflects these setbacks, with analysts noting that the market is unlikely to reward the stock with a higher multiple without evidence of pipeline improvement [17] - Positive results were reported for Sanofi's experimental medicine amlitelimab in Phase 3 clinical studies for atopic dermatitis, indicating potential for future growth [18]

Company Overview - Kimberly-Clark Corporation (NASDAQ:KMB) is one of the largest consumer goods companies in America [2] - The company's shares have decreased by 23% over the past year and by 1.4% year-to-date [2] Analyst Ratings - Bank of America has reduced the firm's share price target to $130 from $148 while maintaining a Buy rating, citing value compression in the sector and that the firm's transformation plan is on track [2] - Citi has lowered its share price target to $90 from $95 and has a Sell rating on the stock [2] Recent Developments - Kimberly-Clark Corporation's shareholders approved the acquisition of Kenvue, with 96% voting in favor [2] - The company raised its quarterly dividend to $1.28 from $1.26, marking the 54th consecutive increase [2] - The dividend increase followed the firm's fourth quarter earnings, which reported a 24% annual growth in adjusted earnings [2] Market Commentary - Jim Cramer highlighted Kimberly-Clark Corporation's dividend as part of a safe dividend portfolio [2]

Core Insights - The transaction represents the largest multifamily closing in the U.S. year-to-date, with Newmark arranging a $690 million loan for West Shore to refinance 13 multifamily properties across multiple states [1] Company Overview - Newmark Group, Inc. is a leading commercial real estate advisor and service provider, generating over $3.1 billion in revenues for the twelve months ended September 30, 2025, and operating approximately 170 offices with over 8,500 professionals globally [6] Transaction Details - The loan secured by Newmark for West Shore is a cash-out, single-asset single-borrower (SASB) refinancing, originated by Citi, marking Newmark's third SASB transaction with West Shore in 15 months, totaling $1.8 billion in loan proceeds [2][3] - The portfolio refinanced includes 4,077 units across various properties in Florida, South Carolina, Tennessee, and Texas, featuring amenities such as pools and fitness centers [4] Market Trends - Multifamily debt originations increased by 37% year-over-year in 2025, with nearly 45% of investment sales activity concentrated in Sun Belt markets [5]

Coinbase Global Inc. (NASDAQ:COIN) CEO Brian Armstrong reportedly faced harsh criticism from Wall Street’s biggest bank chiefs at the World Economic Forum in Davos.The Davos ShowdownJPMorgan Chase (NYSE:JPM) CEO Jamie Dimon interrupted Armstrong’s coffee meeting with former U.K. Prime Minister Tony Blair to confront him directly according to a Wall Street Journal feature published on Friday.“You are full of s—,” Dimon said with his index finger pointed at Armstrong’s face, telling him to stop lying on telev ...